SARS-CoV-2 Vaccination in Androgen Sensitive Phenotypes – A Study on Associated Factors for SARS-CoV-2 Vaccination and Its Adverse Effects Among Androgenetic Alopecia and Benign Prostate Hyperplasia Patients

The study examined factors affecting SARS-CoV-2 vaccination and its side effects in 742 androgenetic alopecia (AGA) and 657 benign prostatic hyperplasia (BPH) patients, with 457 AGA and 397 BPH completing the survey. It found that 92.8% of AGA and 61.0% of BPH patients received at least one vaccine dose. Anti-androgen therapy and comorbidities reduced vaccination rates in AGA patients, while age was significant for BPH patients. Adverse reactions varied by vaccine type and anti-androgen therapy, with injection site pain being most common. The study suggests anti-androgen therapy may enhance immunity and reduce COVID-19 susceptibility but increases injection site pain. It calls for more data on SARS-CoV-2 specific IgG levels in patients on anti-androgen therapy and highlights the need for targeted education to improve vaccination rates in these groups. Limitations include recall bias and a small, single-center population.